SeaSpine® Announces Full Commercial Launch of Explorer® TO

CARLSBAD, Calif., April 28, 2022 (GLOBE NEWSWIRE) — SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company specializing in surgical solutions for the treatment of spinal disorders, today announced the full commercial launch of the Explorer® Expandable interbody system TO (TLIF Oblique).

The Explorer TO Expandable Interbody System offers an innovative and elegant posterior interbody solution that offers two types of implants – one extending in height, the other in lordosis – compatible with the same instrumentation. Notably, Explorer TO is designed to streamline the delivery of allografts or autografts after implantation and expansion.

Explorer TO represents SeaSpine’s first expandable interbody system from the Explorer family. Building on the company’s core Explorer technology, SeaSpine plans to launch additional expandable interbody systems that will accommodate different approaches and techniques in the future and collectively address a market segment that SeaSpine estimated at over $450 million in the United States alone.

“As a minimally invasive spine surgeon, I’m always looking for an interbody device that minimizes tissue and nerve disruption, while maximizing height restoration,” said Dr. Azam Basheer of the Henry Ford Hospital. “Despite the cage’s slim profile and tapered nose, it provides an immense amount of continuous distraction force to maximize foraminal height and restore sagittal balance.”

“We designed Explorer TO with minimally invasive and complex open deformity surgeons in mind, meeting both the TLIF and PLIF requirements required for profile, sturdiness and post-packaging,” said Shaeffer Bannigan, Vice-Principal President, Product Development. “This new product offering allows SeaSpine to compete in the expandable interbody market in a much more efficient and comprehensive manner than we have been able to in the past.”

About Sea Spine

SeaSpine ( is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients with spinal disorders. SeaSpine’s comprehensive procedural solutions include its market-leading FLASH™ navigation, a system designed to improve screw placement accuracy and provide a cost-effective, time-saving and radiation-free solution for surgical navigation, as well as a comprehensive portfolio of spinal and orthobiologic implants to meet the diverse product combinations that neurosurgeons and orthopedic spine surgeons need to facilitate spinal fusion in minimally invasive degenerative surgery (MIS) and complex spinal deformity procedures on the lumbar, thoracic and cervical spine. With its product development expertise in the areas of advanced optics, software, orthobiologic sciences and spinal implants, SeaSpine can offer its surgeon customers a complete solution to meet the evolving clinical needs of their patients. SeaSpine currently markets its products in the United States and in approximately 30 countries around the world.

Forward-looking statements
SeaSpine cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements based on the company’s current expectations and assumptions. These forward-looking statements include, but are not limited to, statements relating to: SeaSpine’s expectations regarding the launch of additional expandable interbody systems that build on the company’s core Explorer technology and that will accommodate different approaches and techniques in the future. Among the factors that could cause or contribute to material differences between the Company’s actual results and the expectations indicated by the forward-looking statements are risks and uncertainties, which include, but are not limited to: the ability of newly launched products to perform as intended and intended and to meet the needs of surgeons and patients, including due to the lack of substantial clinical validation of the products following a limited commercial launch (or “alpha”); unexpected delay, including due to new product development and launch support, including the fact that newly launched products may require substantial additional development activities, which could introduce further delay, or as a result of the obtaining regulatory authorizations; and other risks and uncertainties more fully described in press releases and the Company’s periodic filings with the Securities and Exchange Commission. The Company’s public filings with the Securities and Exchange Commission are available at

You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they were made. SeaSpine does not intend to revise or update the forward-looking statements set forth in this press release to reflect events or circumstances occurring after the date hereof, except as required by law.

Investor Relations
Leigh Salve
(415) 937-5402
[email protected]

A photo accompanying this announcement is available at

Comments are closed.